Olaparib plus bevacizumab first-line maintenance in ovarian cancer : final overall survival results from the PAOLA-1/ENGOT-ov25 trial

MLA

I. Ray-Coquard, et al. Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer : Final Overall Survival Results from the PAOLA-1/ENGOT-Ov25 Trial. Jan. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c9bbaa7294fdcc174f2e4ad3f936afdf&authtype=sso&custid=ns315887.

APA

I. Ray-Coquard, A. Leary, S. Pignata, C. Cropet, A. González-Martin, C. Marth, S. Nagao, I. Vergote, N. Colombo, J. Mäenpää, F. Selle, J. Sehouli, D. Lorusso, E.M. Guerra Alia, G. Bogner, H. Yoshida, C. Lefeuvre-Plesse, P. Buderath, A.M. Mosconi, … P. Harter. (2023). Olaparib plus bevacizumab first-line maintenance in ovarian cancer : final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Chicago

I. Ray-Coquard, A. Leary, S. Pignata, C. Cropet, A. González-Martin, C. Marth, S. Nagao, et al. 2023. “Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer : Final Overall Survival Results from the PAOLA-1/ENGOT-Ov25 Trial,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c9bbaa7294fdcc174f2e4ad3f936afdf&authtype=sso&custid=ns315887.